"The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSS"...
LEVULAN Photodynamic Therapy for Actinic Keratoses.
The first step in LEVULAN KERASTICK (aminolevulinic acid) photodynamic therapy (PDT) for actinic keratoses is application of the LEVULAN KERASTICK (aminolevulinic acid) Topical Solution to actinic keratoses located on the patient's face or scalp. After LEVULAN KERASTICK (aminolevulinic acid) Topical Solution is applied to the actinic keratoses in the doctor's office, the patient will be told to return the next day. During this time the actinic keratoses will become sensitive to light (photosensitive). Care should be taken to keep the treated actinic keratoses dry and out of bright light. After LEVULAN KERASTICK (aminolevulinic acid) Topical Solution is applied, it is important for the patient to wear lightprotective clothing, such as a wide-brimmed hat, when exposed to sunlight or sources of light. Fourteen to eighteen hours after application of LEVULAN KERASTICK (aminolevulinic acid) Topical Solution the patient will return to the doctor's office to receive blue light treatment, which is the second and final step in the treatment. Prior to blue light treatment, the actinic keratoses will be rinsed with tap water. The patient will be given goggles to wear as eye protection during the blue light treatment. The blue light is of low intensity and will not heat the skin. However, during the light treatment, which lasts for approximately 17 minutes, the patient will experience sensations of tingling, stinging, prickling or burning of the treated lesions. These feelings of discomfort should improve at the end of the light treatment. Following treatment, the actinic keratoses and, to some degree, the surrounding skin, will redden, and swelling and scaling may also occur. However, these lesion changes are temporary and should completely resolve by 4 weeks after treatment.
After LEVULAN KERASTICK (aminolevulinic acid) Topical Solution is applied to the actinic keratoses in the doctor's office, the patient should avoid exposure of the photosensitive actinic keratoses to sunlight or bright indoor light (e.g., from examination lamps, operating room lamps, tanning beds, or lights at close proximity) during the period prior to blue light treatment. If the patient feels stinging and/or burning on the actinic keratoses, exposure to light should be reduced. Before going into sunlight, the patient should protect treated lesions from the sun by wearing a wide-brimmed hat or similar head covering of light-opaque material. Sunscreens will not protect the patient against photosensitivity reactions.
If for any reason the patient cannot return for blue light treatment during the prescribed period after application of LEVULAN KERASTICK (aminolevulinic acid) Topical Solution (14 to 18 hours), the patient should call the doctor. The patient should also continue to avoid exposure of the photosensitized lesions to sunlight or prolonged or intense light for at least 40 hours. If stinging and/or burning is noted, exposure to light should be reduced.
Last reviewed on RxList: 10/8/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Levulan Kerastick Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.